🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I finally found time to do this.

Honored and grateful to make the Web of Science #Clarivate list of highly cited researchers for 2024!!! Full list here: clarivate.com/highly-cited-r… #HighlyCited2024 Clarivate Clarivate for Academia & Government VA Research

How the Pandemic Increased US Deaths! Visualized in 8 charts by Jason Gale in Bloomberg 1. The Covid Pandemic Fueled a 4-Year Mortality Surge in the US

In a very large dataset of people with diabetes treated with GLP-1 drugs cf other medications, there were benefits seen for reduced clotting disorders, seizures, neurocognitive disorders (including Alzheimer's), by Ziyad Al-Aly, MD and colleagues Nature Medicine nature.com/articles/s4159…

1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By Yan Xie, Taeyoung Choi and me 🧵 nature.com/articles/s4159…

I sat down with Dana Parish to talk about this and more. x.com/danaparish/sta…

Excellent piece by Carolyn Barber, MD fortune.com/well/article/o…

Let me address this. We wrote the grant to do this project in 2018. It was funded in 2020. We deliberately delayed this to devote time and effort to addressing Covid and Long Covid. My team and I remain committed to working on LC, but we cannot default on our other commitments.

Great coverage by Jason Gale in Bloomberg Free link here: shorturl.at/4yos8

Large study of #GLP1 users over many years by Ziyad Al-Aly, MD and his team has uncovered more benefits (especially related to addiction and neuropsychiatric disorders) than risks in veterans.

🚨 New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (weight loss drugs) across 175 health conditions. 📄 Free access to the full study: rdcu.be/d6VYU 🧵 Explore the key findings: x.com/zalaly/status/…

🚨 I dive into the benefits and risks of Ozempic and similar weight loss drugs in this article for The Conversation U.S. 💊 These drugs may lower the risk of 42 health conditions but aren’t without risks theconversation.com/ozempic-and-si… Free PDF of original article rdcu.be/d6VYU

🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. nature.com/articles/s4159…

I applaud Robert F. Kennedy Jr commitment to prioritizing funding for Long Covid. We stand ready to work with you to address the needs of Americans impacted by Long Covid. Thanks to Senator Todd Young for raising this important question. youtu.be/x3I8CKL4T1Q?si… via YouTube

To the community: A ‘yes’ to supporting Long Covid research is better than a ‘no.’ We will hold him to it—and I stand ready to work with him if he’s serious about advancing research and care for those impacted by Long Covid.

Thanks to Derek Thompson for hosting me on his podcast. We talked about the GLP-1 and more. Details in this post below.

I talked to Dani Blum from The New York Times about the potential role of GLP-1 drugs on Alzheimer’s disease. They seem promising, but more data is needed for sure. nytimes.com/2025/01/31/wel…

For decades, the junk food industry has deliberately engineered foods to be addictive. Ozempic and other GLP-1 drugs have helped people break free from this cycle. In response, the industry is now searching for ways to counteract the effects of these medications, aiming to design

It gets wilder. One of the researchers who is helping design this new generation of addictive foods is on GLP-1!!!!!!!

Honored to speak at Harvard University’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing